menu
    • menu

    Company profile for Enlivex Therapeutics

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerou...
    Our mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body’s native mechanisms to restore – rather than suppress –

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Enlivex TherapeuticsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    14 Einstein St. Nes-Ziona 7403618
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://enlivex.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enlivex-therapeutics-nasdaq-enlv
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enlivex Rain Launches an OpenClaw and AI Agent Interface
    Enlivex Rain Launches an OpenClaw and AI Agent Interface

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263007/0/en/Enlivex-Rain-Update-Rain-Launches-an-OpenClaw-and-AI-Agent-Interface-Allowing-Anyone-To-Create-A-Prediction-Market-Via-A-Single-Prompt.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Enlivex Reports Full-Year 2025 Results
    Enlivex Reports Full-Year 2025 Results

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262187/0/en/Enlivex-Reports-Full-Year-2025-Results-Profit-Net-Income-of-1-23-Billion-and-Diluted-Earnings-Per-Share-EPS-of-25-48.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Enlivex Announces $21 M Debt Financing, $20M Share Repurchase
    Enlivex Announces $21 M Debt Financing, $20M Share Repurchase

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261234/0/en/Enlivex-Announces-21-Million-Debt-Financing-Decentralized-Prediction-Markets-RAIN-Token-Related-Updates-and-20-Million-Share-Repurchase-Program.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Enlivex Secures FDA IND for Allocetra Phase 2b Knee OA Trial
    Enlivex Secures FDA IND for Allocetra Phase 2b Knee OA Trial

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260316/0/en/Quality-Longevity-Company-Enlivex-Receives-Investigational-New-Drug-IND-Clearance-from-the-FDA-for-Phase-2b-Trial-of-Allocetra-in-Age-Related-Primary-Moderate-to-Severe-Knee-Osteoa.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Enlivex Updates Treasury: RAIN Token Listed On Kraken Exchange
    Enlivex Updates Treasury: RAIN Token Listed On Kraken Exchange

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235274/0/en/Enlivex-Treasury-Portfolio-Update-New-Listing-of-the-RAIN-Token-on-Kraken-the-Second-Largest-U-S-Cryptocurrency-Exchange.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Enlivex Updates Treasury: RAIN Token Listed On Whitebit Exchange
    Enlivex Updates Treasury: RAIN Token Listed On Whitebit Exchange

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225595/0/en/Enlivex-Treasury-Portfolio-Update-Listing-of-the-RAIN-Token-on-WhiteBIT-a-Leading-Cryptocurrency-Exchange.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search